Physician profile
Robert J Mittman
NPI 1821166877
$66,318.57
in general payments reported to CMS, 2019-2025
65 companies · $8,789 in 2025
The $8,789 reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $11K · 2021: $8,968 · 2022: $7,534 · 2023: $7,648 · 2024: $7,412 · 2025: $8,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,120 · Consulting Fee: $1,112 · Education: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21,102.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,120.00 |
| Consulting Fee | $1,112.00 |
| Education | $515.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,026.20 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Glaxosmithkline, LLC. | $8,461.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $6,348.01 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Pfizer INC. | $5,299.37 | 2019-2025 | |
| Genzyme Corporation | $4,914.41 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $2,442.38 | 2021-2025 | Orladeyo |
| Amgen INC. | $2,287.05 | 2021-2025 | Repatha, Tezspire, Otezla |
| Abbvie INC. | $2,030.50 | 2021-2025 | |
| Grifols USA, LLC | $2,029.57 | 2019-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Regeneron Healthcare Solutions, INC. | $1,535.88 | 2019-2025 | Dupixent |
| Cycle Pharmaceuticals INC | $1,170.00 | 2024-2025 | Sajazir, Sajazir |
| Incyte Corporation | $1,112.82 | 2021-2025 | Opzelura, Opzelura |
| Horizon Therapeutics Plc | $1,069.10 | 2019-2022 | |
| Tersera Therapeutics LLC | $1,007.13 | 2022-2025 | Quzyttir |
| Csl Behring | $757.98 | 2019-2025 | Haegarda, Hizentra, Andembry |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $722.17 | 2019-2025 | |
| Medimetriks Pharmaceuticals, INC. | $700.00 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $699.56 | 2020-2025 | Glassia, Trintellix, Takhzyro |
| Novo Nordisk INC | $626.15 | 2019-2024 | Rybelsus, Ozempic |
| Mylan Specialty L.P. | $451.41 | 2019-2023 | Yupelri |
| Pharming Healthcare, INC. | $430.55 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $395.60 | 2019-2021 | |
| Leo Pharma INC. | $384.59 | 2022-2025 | Adbry, Anzupgo |
| Biohaven Pharmaceuticals, INC. | $367.53 | 2021 | |
| Ani Pharmaceuticals, INC. | $350.00 | 2023 | Veregen |
| Scilex Pharmaceuticals INC. | $328.46 | 2023-2025 | Ztlido |
| Electromed, INC. | $298.86 | 2022-2025 | Smartvest |
| Philips North America LLC | $298.36 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $265.04 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $262.59 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $259.38 | 2019-2023 | Cinqair |
| Sunovion Pharmaceuticals INC. | $248.01 | 2019-2021 | |
| Kaleo, INC. | $198.92 | 2019-2023 | Auvi-Q |
| Currax Pharmaceuticals LLC | $198.33 | 2021-2025 | Contrave, Onzetra Xsail |
| Epi Health, LLC | $191.29 | 2019-2022 | |
| Alk-Abello, INC | $189.21 | 2019-2022 | |
| Axsome Therapeutics, INC. | $171.41 | 2023 | Auvelity |
| Allergan, INC. | $164.50 | 2020-2021 | |
| Bio Products Laboratory USA, INC. | $139.66 | 2020-2023 | Coagadex, Gammaplex |
| Vifor Pharma, INC. | $134.80 | 2024-2025 | Zemaira |
| Blueprint Medicines Corporation | $130.90 | 2023 | Ayvakit |
| Octapharma USA, INC. | $126.06 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $124.36 | 2019-2021 | |
| Lilly USA, LLC | $115.69 | 2023-2025 | Mounjaro, Ebglyss, Zepbound |
| Dermavant Sciences, INC. | $110.47 | 2023 | Vtama |
| Shire North American Group INC | $84.15 | 2019 | |
| Redhill Biopharma INC. | $67.28 | 2020-2022 | |
| Organon LLC | $57.14 | 2025 | Vtama |
| Circassia INC. | $55.45 | 2019 | |
| Verona Pharma, INC. | $55.40 | 2025 | Ohtuvayre |
| Aytu Biopharma, INC. | $48.70 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $47.87 | 2024-2025 | Zoryve |
| Hikma Pharmaceuticals USA | $40.09 | 2021-2022 | |
| Galderma Laboratories, L.P. | $39.87 | 2024-2025 | Nemluvio |
| Biocryst Pharmaceuticals, INC. | $38.21 | 2020 | |
| Protega Pharmaceutials INC | $37.46 | 2025 | Roxybond |
| Invivyd INC | $25.91 | 2025 | Pemgarda |
| Gc Biopharma USA, INC. | $23.08 | 2025 | Alyglo |
| Azurity Pharmaceuticals, INC. | $23.03 | 2025 | Edarbi |
| Merck Sharp & Dohme LLC | $20.02 | 2023 | |
| Eyevance Pharmaceuticals LLC | $18.67 | 2021 | |
| Esperion Therapeutics, INC. | $18.46 | 2025 | Nexletol |
| Bausch Health US, LLC | $15.59 | 2019 | |
| Zyla Life Sciences, INC. | $14.39 | 2019 | |
| Phadia US INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mittman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.